Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Markus Loeffler, Bernd Metzner et al.|The Lancet Oncology|2008Cited by 1.1k
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Michael Unterhalt, Martin Dreyling et al.|Blood|2007Cited by 971
<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study GroupVerena I. Gaidzik, Konstanze Döhner, Lars Bullinger et al.|Journal of Clinical Oncology|2011Cited by 450
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al.|Leukemia|2012Cited by 417
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVRüdiger Hehlmann, Andreas Hochhaus, Martin C. Müller et al.|Journal of Clinical Oncology|2013Cited by 299